替格瑞洛相比氯吡格雷治疗急性冠状动脉综合征的医疗成本分析

Cost Analysis of Ticagrelor vs Clopidogrel for the Treatment of Acute Coronary Syndromes

目的从卫生服务提供者的角度,结合2016年全国层面的成本数据,对替格瑞洛和氯吡格雷治疗急性冠状动脉综合征(ACS)的医疗成本及成本结构进行测算和分析。方法参照PLATO试验的分组、治疗方案和医疗资源使用情况,结合中国的医疗成本数据,计算替格瑞洛组和氯吡格雷组患者12个月的医疗成本,并对成本和成本构成进行比较分析。结果除药品成本外,替格瑞洛组患者12个月人均医疗成本为20 058.42元,氯吡格雷组为20 948.05元,治疗成本是医疗成本(不包括药品成本)中最主要的构成部分,占比约为86%。替格瑞洛组较氯吡格雷组节约成本889.63元,说明治疗成本的节约是最主要的节约因素。结论从卫生服务提供者的角度,替格瑞洛相比于氯吡格雷可以节约ACS治疗的医疗成本(不包括药品成本),治疗成本的节约是最主要的节约因素。

Objective To conduct a cost analysis of ticagrelor vs clopidogrel for the treatment of acute coronary syndromes（ACS） based on 2016 national health service cost data in China from the respective of health care providers.Methods The 12 months cost of ticagrelor/clopidogrel in treating ACS per capita was calculated by using resource use data from PLATO trial and cost data from CHIRA database.Hospitalization cost and cost structure were compared and analyzed.Results Excluding the cost of drugs,the 12 months hospitalization cost per capita of ticagrelor group and clopidogrel group were 20 058.42 CNY and 20 948.05 CNY.Intervention cost was the main component. Compared with clopidogrel group,ticagrelor group could help to save 889.63 CNY for 12 months ACS treatment per capita,while intervention cost was the main saving causation.Conclusion Ticagrelor could help to save hospitalization cost（excluding drug cost） compared with clopidogrel in treating ACS. Intervention cost was the main saving causation.